12 research outputs found
Recommended from our members
A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression.
Metastasis depends upon cancer cell growth and survival within the metastatic niche. Tumors which remodel their glycocalyces, by overexpressing bulky glycoproteins like mucins, exhibit a higher predisposition to metastasize, but the role of mucins in oncogenesis remains poorly understood. Here we report that a bulky glycocalyx promotes the expansion of disseminated tumor cells in vivo by fostering integrin adhesion assembly to permit G1 cell cycle progression. We engineered tumor cells to display glycocalyces of various thicknesses by coating them with synthetic mucin-mimetic glycopolymers. Cells adorned with longer glycopolymers showed increased metastatic potential, enhanced cell cycle progression, and greater levels of integrin-FAK mechanosignaling and Akt signaling in a syngeneic mouse model of metastasis. These effects were mirrored by expression of the ectodomain of cancer-associated mucin MUC1. These findings functionally link mucinous proteins with tumor aggression, and offer a new view of the cancer glycocalyx as a major driver of disease progression
Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins
Targeted protein degradation is a powerful strategy to address the canonically undruggable proteome. However, current technologies are limited to targets with cytosolically-accessible and ligandable domains. Here, we designed and synthesized conjugates capable of binding both a cell surface lysosome targeting receptor and the extracellular domain of a target protein. These lysosome targeting chimeras (LYTACs) consist of an antibody fused to agonist glycopeptide ligands for the cation-independent mannose-6-phosphate receptor (CI-M6PR). LYTACs enabled a CRISPRi knockdown screen revealing the biochemical pathway for CI-M6PR-mediated cargo internalization. We demonstrated that LYTACs mediate efficient degradation of Apolipoprotein-E4, epidermal growth factor receptor (EGFR), CD71, and programmed death-ligand 1 (PD-L1). LYTACs represent a modular strategy for directing secreted and membrane proteins for degradation in the context of both basic research and therapy. </p
An Enzymatic Toolkit for Selective Proteolysis, Detection, and Visualization of Mucin-Domain Glycoproteins
Densely O-glycosylated mucin domains are found in a broad range of cell surface and secreted proteins, where they play key physiological roles. In addition, alterations in mucin expression and glycosylation are common in a variety of human diseases, such as cancer, cystic fibrosis, and inflammatory bowel diseases. These correlations have been challenging to uncover and establish because tools that specifically probe mucin domains are lacking. Here, we present a panel of bacterial proteases that cleave mucin domains via distinct peptide- and glycan-based motifs, generating a diverse enzymatic toolkit for mucin-selective proteolysis. By mutating catalytic residues of two such enzymes, we engineered mucin-selective binding agents with retained glycoform preferences. StcEE447D is a pan-mucin stain derived from enterohemorrhagic Escherichia coli that is tolerant to a wide range of glycoforms. BT4244E575A derived from Bacteroides thetaiotaomicron is selective for truncated, asialylated Core 1 structures commonly associated with malignant and pre-malignant tissues. We demonstrated that these catalytically inactive point mutants enable robust detection and visualization of mucin-domain glycoproteins by flow cytometry, Western blot, and immunohistochemistry. Application of our enzymatic toolkit to ovarian cancer patient ascites fluid and tissue slices facilitated characterization of patients based on differences in mucin cleavage and expression patterns.</p
A Mucin-Specific Protease Enables Molecular and Functional Analysis of Human Cancer-Associated Mucins
Mucins are a class of highly O-glycosylated proteins that are ubiquitously expressed on cellular
surfaces and are important for human health, especially in the context of carcinomas. However,
the molecular mechanisms by which aberrant mucin structures lead to tumor progression and
immune evasion have been slow to come to light, in part because methods for selective mucin
degradation are lacking. Here we employ high resolution mass spectrometry, polymer synthesis,
and computational peptide docking to demonstrate that a bacterial protease, called StcE,
cleaves mucin domains by recognizing a discrete peptide-, glycan-, and secondary structure-
based motif. We exploited StcE’s unique properties to map glycosylation sites and structures of
purified and recombinant human mucins by mass spectrometry. As well, we found that StcE will
digest cancer-associated mucins from cultured cells and from ovarian cancer patient-derived
ascites fluid. Finally, using StcE we discovered that Siglec-7, a glyco-immune checkpoint
receptor, specifically binds sialomucins as biological ligands, whereas the related Siglec-9
receptor does not. Mucin-specific proteolysis, as exemplified by StcE, is therefore a powerful
tool for the study of glycoprotein structure and function and for deorphanizing mucin-binding
receptors.
</div
Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx
The mammalian glycocalyx is a heavily glycosylated extramembrane compartment found on
nearly every cell. Despite its relevance in both health and disease, studies of the glycocalyx
remain hampered by a paucity of methods to spatially classify its components. We combine
metabolic labeling, bioorthogonal chemistry, and super-resolution localization microscopy to
image two constituents of cell-surface glycans, N-acetylgalactosamine (GalNAc) and sialic acid,
with 10-20 nm precision in 2D and 3D. This approach enables two measurements: glycocalyx
height and the distribution of individual sugars distal from the membrane. These measurements
show that the glycocalyx exhibits nanoscale architecture, on both cell lines and primary human
tumor cells. Additionally, we observe enhanced glycocalyx height in response to epithelial-to-
mesenchymal transition and to oncogenic KRAS activation. In the latter case, we trace increased
height to an effector gene, GALNT7. These data highlight the power of advanced imaging
methods to provide molecular and functional insights into glycocalyx biology.
</div
Recommended from our members
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins.
Mucin domains are densely O-glycosylated modular protein domains that are found in a wide variety of cell surface and secreted proteins. Mucin-domain glycoproteins are known to be key players in a host of human diseases, especially cancer, wherein mucin expression and glycosylation patterns are altered. Mucin biology has been difficult to study at the molecular level, in part, because methods to manipulate and structurally characterize mucin domains are lacking. Here, we demonstrate that secreted protease of C1 esterase inhibitor (StcE), a bacterial protease from Escherichia coli, cleaves mucin domains by recognizing a discrete peptide- and glycan-based motif. We exploited StcEs unique properties to improve sequence coverage, glycosite mapping, and glycoform analysis of recombinant human mucins by mass spectrometry. We also found that StcE digests cancer-associated mucins from cultured cells and from ascites fluid derived from patients with ovarian cancer. Finally, using StcE, we discovered that sialic acid-binding Ig-type lectin-7 (Siglec-7), a glycoimmune checkpoint receptor, selectively binds sialomucins as biological ligands, whereas the related receptor Siglec-9 does not. Mucin-selective proteolysis, as exemplified by StcE, is therefore a powerful tool for the study of mucin domain structure and function
Recommended from our members
Design of a mucin-selective protease for targeted degradation of cancer-associated mucins.
Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Here, to expand the landscape of targetable substrates, we designed degraders that achieve substrate selectivity via recognition of a discrete peptide and glycan motif and achieve cell-type selectivity via antigen-driven cell-surface binding. We applied this approach to mucins, O-glycosylated proteins that drive cancer progression through biophysical and immunological mechanisms. Engineering of a bacterial mucin-selective protease yielded a variant for fusion to a cancer antigen-binding nanobody. The resulting conjugate selectively degraded mucins on cancer cells, promoted cell death in culture models of mucin-driven growth and survival, and reduced tumor growth in mouse models of breast cancer progression. This work establishes a blueprint for the development of biologics that degrade specific protein glycoforms on target cells
Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2
This protocol describes a method to obtain spatially resolved proteomic maps of specific compartments within living mammalian cells. An engineered peroxidase, APEX2, is genetically targeted to a cellular region of interest. Upon the addition of hydrogen peroxide for 1 min to cells preloaded with a biotin-phenol substrate, APEX2 generates biotin-phenoxyl radicals that covalently tag proximal endogenous proteins. Cells are then lysed, and biotinylated proteins are enriched with streptavidin beads and identified by mass spectrometry. We describe the generation of an appropriate APEX2 fusion construct, proteomic sample preparation, and mass spectrometric data acquisition and analysis. A two-state stable isotope labeling by amino acids in cell culture (SILAC) protocol is used for proteomic mapping of membrane-enclosed cellular compartments from which APEX2-generated biotin-phenoxyl radicals cannot escape. For mapping of open cellular regions, we instead use a 'ratiometric' three-state SILAC protocol for high spatial specificity. Isotopic labeling of proteins takes 5–7 cell doublings. Generation of the biotinylated proteomic sample takes 1 d, acquiring the mass spectrometric data takes 2–5 d and analysis of the data to obtain the final proteomic list takes 1 week.National Science Foundation (U.S.) (NSF Graduate Research Fellowship)United States. Dept. of Defense (National Defense Science and Engineering Graduate Fellowship)National Institutes of Health (U.S.) ((NIH R01 CA186568)Howard Hughes Medical Institute (Collaborative Initiative Award